(VIANEWS) – Shares of MDXHEALTH (BEL 20: MDXH.BR) fell by a staggering 24.53% in 10 sessions from €0.37 to €0.28 at 10:24 EST on Thursday, following the last session’s upward trend. BEL 20 is dropping 0.72% to €3,639.54, following the last session’s downward trend.
MDXHEALTH’s last close was €0.28, 71.39% under its 52-week high of €0.97.
About MDXHEALTH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Earnings Per Share
As for profitability, MDXHEALTH has a trailing twelve months EPS of €-0.282.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -156.7%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MDXHEALTH’s stock is considered to be overbought (>=80).
More news about MDXHEALTH (MDXH.BR).
